OncoMatch/Clinical Trials/NCT06405425
A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Is NCT06405425 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including BL-B01D1 and PD-1 for urothelial carcinoma.
Treatment: BL-B01D1 · PD-1 — This study is a phase II clinical study to explore the efficacy and safety of BL-B01D1 + PD-1 combination therapy in patients with locally advanced or metastatic urothelial carcinoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Urothelial Carcinoma
Biomarker criteria
Required: PD-L1 (CD274) any tested (testing required; no eligibility threshold specified)
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: antibody-drug conjugate
Exception: ADC with TOPI inhibitors as toxin
Prior ADC recipients with TOPI inhibitors as toxin
Cannot have received: immunotherapy
Exception: prior immunotherapy with grade ≥3 irAE or grade ≥2 immune-related myocarditis
Prior immunotherapy with grade ≥3 irAE or grade ≥2 immune-related myocarditis
Cannot have received: radiation therapy
Exception: palliative radiotherapy within 2 weeks before the first dose
Palliative radiotherapy within 2 weeks before the first dose
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06405425 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require CD274?
Yes, CD274 any tested is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages